| |
First and foremost, I would like to thank you for extending your kind offer
to keep us updated with HCV situations in the US. I am a market researcher
of HCV market in the US, and found your website most informative, and very
easy to understand scientific infron which could be intimidating.
My question is as follows:
Japanese insurance provider does not consider patients with significantly
high viral load (over 12000k IU) as candidates for IFN treatment, and
physicians do not prescribe IFN to patients, since patients with high viral
load are known as non responders.
I was wondering if there is a similar standard to the application of
insurance, as well as physicians' prescribing behaviours. Any feedback
from
you will be greatly appreciated.
Thank you in advance for your support.
|
|
